A Single-Arm, Open-Label Phase II Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma.

Abstract

BACKGROUND:

ONC201 is a small molecule that can cause nonapoptotic cell death through loss of mitochondrial function. Results from the phase I/II trials of ONC201 in patients with refractory solid tumors demonstrated tumor responses and prolonged stable disease in some patients.

METHODS:

This single-arm, open-label, phase II clinical trial evaluated the efficacy of ONC201 at the recommended phase II dose (RP2D) in patients with recurrent or refractory metastatic breast or endometrial cancer. Fresh tissue biopsies and blood were collected at baseline and at cycle 2 day 2 for correlative studies.

RESULTS:

Twenty-two patients were enrolled; 10 patients with endometrial cancer, 7 patients with hormone receptor-positive breast cancer, and 5 patients with triple-negative breast cancer. The overall response rate was 0%, and the clinical benefit rate, defined by complete response (CR) + partial response (PR) + stable disease (SD), was 27% (n = 3/11). All patients experienced an adverse event (AE), which was primarily low grade. Grade 3 AEs occurred in 4 patients; no grade 4 AEs occurred. Tumor biopsies did not show that ONC201 consistently induced mitochondrial damage or alterations in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or the TRAIL death receptors. ONC201 treatment caused alterations in peripheral immune cell subsets.

CONCLUSION:

ONC201 monotherapy did not induce objective responses in recurrent or refractory metastatic breast or endometrial cancer at the RP2D dose of 625 mg weekly but had an acceptable safety profile (ClinicalTrials.gov Identifier: NCT03394027).

• Authors: Sarah L P Atkins, Yoshimi Endo Greer, Sarah Jenkins, Margaret E Gatti-Mays, Nicole Houston, Sunmin Lee, Min-Jung Lee, Shraddha Rastogi, Nahoko Sato, Christina Burks, Christina M Annunziata, Jung-Min Lee, Kunio Nagashima, Jane B Trepel, Stanley Lipkowitz, Alexandra S Zimmer
• Journal: The oncologist (Oncologist) Vol. 28 Issue 10 Pg. 919-e972 (10 03 2023) ISSN: 1549-490X [Electronic] England
• PMID: 37279797 (Publication Type: Clinical Trial, Phase II, Journal Article, Research Support, N.I.H., Intramural, Research Support, Non-U.S. Gov't)
• Copyright: Published by Oxford University Press 2023.

Chemical References

• Antineoplastic Agents
• TIC10 compound

Topics

• Female
• Humans
• Antineoplastic Agents (adverse effects)
• Neoplasm Recurrence, Local (drug therapy)
• Endometrial Neoplasms (drug therapy)
• Triple Negative Breast Neoplasms (drug therapy, pathology)